Abstract
Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.
Original language | English (US) |
---|---|
Pages (from-to) | 1989-1995 |
Number of pages | 7 |
Journal | Future Oncology |
Volume | 15 |
Issue number | 17 |
DOIs | |
State | Published - Jun 2019 |
Keywords
- 10-day decitabine
- acute myeloid leukemia
- frail patients
- hypomethylating agents
- older adults
- overall survival
ASJC Scopus subject areas
- Oncology
- Cancer Research